DDR2 and lung carcinoma: Consequently, an adequate decoration of these structures has allowed us to describe compounds with activities in the nanomolar range as BCR kinase (Breakpoint Cluster Region protein) inhibitors for B lymphoid malignancies (compound 62) [42], DDR2 (Discoidin Domain-containing Receptor 2) inhibitors for treatment of lung cancer (compound 63) [106], and even as HCV (Hepatitis C Virus) inhibitors (compound 64) [31], and others (Figure 20).